Health Utility Values of Canadian Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Author(s)
MEIR LEVI, M.Sc.;
MUHC - McGill University Health Center, Cedars Cancer Centre, Montreal, QC, Canada
MUHC - McGill University Health Center, Cedars Cancer Centre, Montreal, QC, Canada
Presentation Documents
OBJECTIVES: The EuroQol 5-Dimension 5-Level (EQ-5D-5L) is a validated tool that assesses health utility (HU) as a measure of health-related quality of life (HRQoL). Contemporary data on HU of Canadian patients with metastatic breast cancer (mBC) by HER2 status is scarce, and thus this study sought to characterize HU values for HER2-negative (HER2-) mBC.
METHODS: A cross-sectional study was conducted at McGill University Health Centre in Quebec. Eligible patients were aged ≥18 years, had at least stable disease, and were on active treatment with a Health Canada-approved regimen for HER2- mBC (any line/time point on treatment). The EQ-5D-5L was administered at each visit, and each record was treated as a unique data point. The HU values were derived using the Canadian algorithm developed by Xie et al., 2016. The EQ-5D-5L measures HRQoL across five domains and is scored on 5 levels. The questionnaire included a visual analogue scale (VAS) where respondents ranked their overall health on scale of 0-100. Secondary outcomes included mean HU in specific subgroups: HER2-low, defined as immunohistochemistry (IHC) 1+ or IHC 2+/fluorescence in situ hybridization (FISH)-negative, and hormone receptor-positive and -negative (HR+ and HR-).
RESULTS: Between December 2022 and July 2023, 115 HER2- data points were included for analysis, representing 47 patients. For these patients, mean age was 60.1 years (SD: 11.7). The majority of patients were on second line of therapy (41.9%). The mean HU overall was 0.78 (SD: 0.16, n=115) and mean VAS was 74.32 (SD: 17.32). For HER2-low (n=98), mean HU was 0.77 (SD: 0.17). In the HR+/HER2- group, mean HU was 0.79 (SD: 0.15, n=84) and in the HR-/HER2- group, mean HU was 0.78 (SD: 0.20, n=31).
CONCLUSIONS: This study provides the first Canadian data on HU values for HER2- mBC patients, including emerging breast cancer classifications such as HER2-low.
METHODS: A cross-sectional study was conducted at McGill University Health Centre in Quebec. Eligible patients were aged ≥18 years, had at least stable disease, and were on active treatment with a Health Canada-approved regimen for HER2- mBC (any line/time point on treatment). The EQ-5D-5L was administered at each visit, and each record was treated as a unique data point. The HU values were derived using the Canadian algorithm developed by Xie et al., 2016. The EQ-5D-5L measures HRQoL across five domains and is scored on 5 levels. The questionnaire included a visual analogue scale (VAS) where respondents ranked their overall health on scale of 0-100. Secondary outcomes included mean HU in specific subgroups: HER2-low, defined as immunohistochemistry (IHC) 1+ or IHC 2+/fluorescence in situ hybridization (FISH)-negative, and hormone receptor-positive and -negative (HR+ and HR-).
RESULTS: Between December 2022 and July 2023, 115 HER2- data points were included for analysis, representing 47 patients. For these patients, mean age was 60.1 years (SD: 11.7). The majority of patients were on second line of therapy (41.9%). The mean HU overall was 0.78 (SD: 0.16, n=115) and mean VAS was 74.32 (SD: 17.32). For HER2-low (n=98), mean HU was 0.77 (SD: 0.17). In the HR+/HER2- group, mean HU was 0.79 (SD: 0.15, n=84) and in the HR-/HER2- group, mean HU was 0.78 (SD: 0.20, n=31).
CONCLUSIONS: This study provides the first Canadian data on HU values for HER2- mBC patients, including emerging breast cancer classifications such as HER2-low.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR84
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology